PHASE II STUDY OF XRT + LOW-DOSE TEMOZOLOMIDE FOLLOWED BY TEMOZOLOMIDE + CPT-11

XRT 低剂量替莫唑胺随后是替莫唑胺 CPT-11 的 II 期研究

• 批准号: 7607532
• 负责人: MINESH P. MEHTA
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607532
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Drug usage; Funding; Glioblastoma; Grant; Institution; Irinotecan/Temozolomide; Newly Diagnosed; Patients; Phase; Phase II Clinical Trials; Radiation therapy; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Work; chemotherapy; killings; neoplastic cell; temozolomide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to accrual. (from www.cancer.gov website) Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. This Phase II trial is studying how well radiation therapy, temozolomide, and irinotecan work in reating patients with newly diagnosed glioblastoma multiforme.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究对应计。 （来自www.cancer.gov网站） 放射疗法使用高能X射线来损害肿瘤细胞。化学疗法中使用的药物（例如替莫唑胺和伊立替康）以不同的方式起作用，以阻止肿瘤细胞分裂，从而停止生长或死亡。将放射疗法与化疗相结合可能会杀死更多的肿瘤细胞。 这项II期试验正在研究放射疗法，替莫唑胺和伊立替康在重新诊断出已诊断为胶质母细胞瘤的患者中的工作良好。